The use of disease-modifying new drugs for multiple sclerosis treatment in private-sector health plans

The aims of this study were to estimate the effects of demographics, location, severity of multiple sclerosis (MS), comorbidities, plan type, coinsurance levels, and time of entry into the sample on the use of disease-modifying agents. A retrospective analysis of medical claims data from 1996 throug...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2004-08, Vol.26 (8), p.1341-1354
Hauptverfasser:	Ozminkowski, Ronald J., Marder, William D., Hawkins, Kevin, Wang, Shaohung, Stallings, Sarah C., Finkelstein, Stan N., Sinskey, Anthony J., Wierz, David
Format:	Artikel
Sprache:	eng
Schlagworte:	access Adolescent Adult Aged Biological and medical sciences Child Child, Preschool Clinical medicine Clinical practice guidelines Comorbidity copayments Deductibles and Coinsurance - statistics & numerical data Disease Drugs Female Health Planning Humans Immunologic Factors - economics Immunologic Factors - therapeutic use Infant Insurance, Pharmaceutical Services - statistics & numerical data Longitudinal studies Male Medical sciences Medicare Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis - epidemiology Multiple Sclerosis - pathology Neurology Pharmacology. Drug treatments Prevalence Proportional Hazards Models Retrospective Studies Severity of Illness Index technological innovation United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!